VEGFA and wet macular degeneration: Around 15 years ago, the introduction and utilization of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) antibodies has tremendously enhanced the treatment options and visual outcome for several eye diseases associated with macular edema, such as neovascular age-related macular degeneration (n-AMD), retinal vein occlusion, and diabetic retinopathy [1–9].